OLIPASS Corporation
OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD… Read more
OLIPASS Corporation (244460) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.065x
Based on the latest financial reports, OLIPASS Corporation (244460) has a cash flow conversion efficiency ratio of -0.065x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-773.55 Million) by net assets (₩11.86 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OLIPASS Corporation - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how OLIPASS Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OLIPASS Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OLIPASS Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spentex Industries Limited
NSE:SPENTEX
|
0.259x |
|
RPM Automotive Group Ltd
AU:RPM
|
0.023x |
|
INTERDIGITAL
BE:IDI
|
0.107x |
|
GUNGNIR RES INC.
F:AMO1
|
N/A |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
N/A |
|
Melkior Resources Inc
PINK:MKRIF
|
-0.097x |
|
MICube Solution Inc
KQ:373170
|
0.050x |
|
Prima Cakrawala Abadi PT
JK:PCAR
|
0.183x |
Annual Cash Flow Conversion Efficiency for OLIPASS Corporation (2016–2024)
The table below shows the annual cash flow conversion efficiency of OLIPASS Corporation from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩11.86 Billion | ₩-9.70 Billion | -0.818x | +86.10% |
| 2023-12-31 | ₩2.49 Billion | ₩-14.67 Billion | -5.881x | -297.30% |
| 2022-12-31 | ₩10.46 Billion | ₩-15.49 Billion | -1.480x | -132.37% |
| 2021-12-31 | ₩30.80 Billion | ₩-19.62 Billion | -0.637x | -36.09% |
| 2020-12-31 | ₩43.44 Billion | ₩-20.34 Billion | -0.468x | +46.13% |
| 2019-12-31 | ₩19.28 Billion | ₩-16.75 Billion | -0.869x | -295.22% |
| 2018-12-31 | ₩-34.80 Billion | ₩-15.49 Billion | 0.445x | +62.39% |
| 2017-12-31 | ₩-42.28 Billion | ₩-11.59 Billion | 0.274x | +61.59% |
| 2016-12-31 | ₩-59.53 Billion | ₩-10.10 Billion | 0.170x | -- |